Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist investors circle. The Lexington, Massachusetts-based biotech, which ...

On Tuesday, Keros Therapeutics (NASDAQ:KROS) faced a downgrade in stock rating from Buy to Neutral by Cantor Fitzgerald. The stock, which has declined nearly 80% over the past year according to ...

Keros Therapeutics’ board of directors has authorised a ‘poison pill defence’— in response to increasing investor interest in “influencing the company’s control”. The move comes ...

Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% in the premarket on Thursday after the biotech commenced a review process to evaluate different strategic options, including a potential sale ...

April 10 (Reuters) - Keros Therapeutics (KROS.O), opens new tab has adopted a poison pill defense to fend off hostile takeovers, after some investors indicated a desire to influence the control of ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to hit a ...

LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical ...

LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to ...